nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—Carmustine—melanoma	0.103	0.229	CbGbCtD
Irbesartan—CYP1A2—Vemurafenib—melanoma	0.0815	0.181	CbGbCtD
Irbesartan—CYP3A4—Temozolomide—melanoma	0.078	0.173	CbGbCtD
Irbesartan—CYP2D6—Vemurafenib—melanoma	0.0672	0.149	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—melanoma	0.0625	0.139	CbGbCtD
Irbesartan—CYP3A4—Vemurafenib—melanoma	0.0427	0.095	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—melanoma	0.0147	0.0326	CbGbCtD
Irbesartan—JUN—skin epidermis—melanoma	0.00613	0.134	CbGeAlD
Irbesartan—JUN—endothelium—melanoma	0.00445	0.097	CbGeAlD
Irbesartan—JUN—blood vessel—melanoma	0.0041	0.0895	CbGeAlD
Irbesartan—AGTR1—endothelium—melanoma	0.00335	0.0731	CbGeAlD
Irbesartan—AGTR1—blood vessel—melanoma	0.00309	0.0674	CbGeAlD
Irbesartan—JUN—neck—melanoma	0.00294	0.064	CbGeAlD
Irbesartan—AGTR1—neck—melanoma	0.00221	0.0482	CbGeAlD
Irbesartan—JUN—eye—melanoma	0.00218	0.0476	CbGeAlD
Irbesartan—JUN—retina—melanoma	0.00216	0.0472	CbGeAlD
Irbesartan—JUN—skin of body—melanoma	0.0019	0.0414	CbGeAlD
Irbesartan—EDNRA—mammalian vulva—melanoma	0.0019	0.0414	CbGeAlD
Irbesartan—JUN—mammalian vulva—melanoma	0.00173	0.0378	CbGeAlD
Irbesartan—PTGS1—endothelium—melanoma	0.00147	0.0321	CbGeAlD
Irbesartan—PTGS1—blood vessel—melanoma	0.00136	0.0296	CbGeAlD
Irbesartan—JUN—head—melanoma	0.00124	0.027	CbGeAlD
Irbesartan—EDNRA—lymph node—melanoma	0.000951	0.0207	CbGeAlD
Irbesartan—AGTR1—head—melanoma	0.000933	0.0204	CbGeAlD
Irbesartan—JUN—lymph node—melanoma	0.000868	0.0189	CbGeAlD
Irbesartan—AGTR1—lymph node—melanoma	0.000654	0.0143	CbGeAlD
Irbesartan—PTGS1—skin of body—melanoma	0.000629	0.0137	CbGeAlD
Irbesartan—PTGS1—mammalian vulva—melanoma	0.000574	0.0125	CbGeAlD
Irbesartan—Connective tissue disorder—Temozolomide—melanoma	0.00048	0.00269	CcSEcCtD
Irbesartan—Urethral disorder—Temozolomide—melanoma	0.000479	0.00269	CcSEcCtD
Irbesartan—Hyponatraemia—Docetaxel—melanoma	0.000471	0.00265	CcSEcCtD
Irbesartan—Visual impairment—Temozolomide—melanoma	0.000471	0.00264	CcSEcCtD
Irbesartan—Erythema—Dactinomycin—melanoma	0.00047	0.00264	CcSEcCtD
Irbesartan—Flushing—Carmustine—melanoma	0.000469	0.00263	CcSEcCtD
Irbesartan—Ill-defined disorder—Bleomycin—melanoma	0.000468	0.00263	CcSEcCtD
Irbesartan—Anaemia—Bleomycin—melanoma	0.000466	0.00262	CcSEcCtD
Irbesartan—Diarrhoea—Vemurafenib—melanoma	0.000464	0.00261	CcSEcCtD
Irbesartan—Tinnitus—Temozolomide—melanoma	0.000455	0.00256	CcSEcCtD
Irbesartan—Malaise—Bleomycin—melanoma	0.000454	0.00255	CcSEcCtD
Irbesartan—Flushing—Temozolomide—melanoma	0.000453	0.00254	CcSEcCtD
Irbesartan—Cardiac disorder—Temozolomide—melanoma	0.000453	0.00254	CcSEcCtD
Irbesartan—Arrhythmia—Carmustine—melanoma	0.000451	0.00253	CcSEcCtD
Irbesartan—Leukopenia—Bleomycin—melanoma	0.000451	0.00253	CcSEcCtD
Irbesartan—Dizziness—Vemurafenib—melanoma	0.000449	0.00252	CcSEcCtD
Irbesartan—Angiopathy—Temozolomide—melanoma	0.000443	0.00249	CcSEcCtD
Irbesartan—Immune system disorder—Temozolomide—melanoma	0.000441	0.00248	CcSEcCtD
Irbesartan—Mediastinal disorder—Temozolomide—melanoma	0.00044	0.00247	CcSEcCtD
Irbesartan—Malnutrition—Carmustine—melanoma	0.00044	0.00247	CcSEcCtD
Irbesartan—Erythema—Carmustine—melanoma	0.00044	0.00247	CcSEcCtD
Irbesartan—Cough—Bleomycin—melanoma	0.00044	0.00247	CcSEcCtD
Irbesartan—Chills—Temozolomide—melanoma	0.000438	0.00246	CcSEcCtD
Irbesartan—Ill-defined disorder—Dactinomycin—melanoma	0.000436	0.00245	CcSEcCtD
Irbesartan—Anaemia—Dactinomycin—melanoma	0.000434	0.00244	CcSEcCtD
Irbesartan—Liver function test abnormal—Docetaxel—melanoma	0.000433	0.00243	CcSEcCtD
Irbesartan—Vomiting—Vemurafenib—melanoma	0.000432	0.00242	CcSEcCtD
Irbesartan—Myalgia—Bleomycin—melanoma	0.000429	0.00241	CcSEcCtD
Irbesartan—Chest pain—Bleomycin—melanoma	0.000429	0.00241	CcSEcCtD
Irbesartan—Orthostatic hypotension—Docetaxel—melanoma	0.000429	0.00241	CcSEcCtD
Irbesartan—Abdominal pain upper—Docetaxel—melanoma	0.000429	0.00241	CcSEcCtD
Irbesartan—Rash—Vemurafenib—melanoma	0.000428	0.0024	CcSEcCtD
Irbesartan—Dermatitis—Vemurafenib—melanoma	0.000428	0.0024	CcSEcCtD
Irbesartan—Headache—Vemurafenib—melanoma	0.000425	0.00239	CcSEcCtD
Irbesartan—Malnutrition—Temozolomide—melanoma	0.000425	0.00239	CcSEcCtD
Irbesartan—Erythema—Temozolomide—melanoma	0.000425	0.00239	CcSEcCtD
Irbesartan—Breast disorder—Docetaxel—melanoma	0.000424	0.00238	CcSEcCtD
Irbesartan—Discomfort—Bleomycin—melanoma	0.000424	0.00238	CcSEcCtD
Irbesartan—Malaise—Dactinomycin—melanoma	0.000424	0.00238	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000423	0.00237	CcSEcCtD
Irbesartan—Cramp muscle—Docetaxel—melanoma	0.000423	0.00237	CcSEcCtD
Irbesartan—Leukopenia—Dactinomycin—melanoma	0.000421	0.00236	CcSEcCtD
Irbesartan—Nasopharyngitis—Docetaxel—melanoma	0.00042	0.00236	CcSEcCtD
Irbesartan—Dysgeusia—Temozolomide—melanoma	0.000416	0.00234	CcSEcCtD
Irbesartan—Vision blurred—Carmustine—melanoma	0.000415	0.00233	CcSEcCtD
Irbesartan—Tremor—Carmustine—melanoma	0.000412	0.00231	CcSEcCtD
Irbesartan—Oedema—Bleomycin—melanoma	0.000411	0.00231	CcSEcCtD
Irbesartan—Anaphylactic shock—Bleomycin—melanoma	0.000411	0.00231	CcSEcCtD
Irbesartan—PTGS1—head—melanoma	0.00041	0.00895	CbGeAlD
Irbesartan—Infection—Bleomycin—melanoma	0.000409	0.00229	CcSEcCtD
Irbesartan—Valsartan—ALB—melanoma	0.000408	0.373	CrCbGaD
Irbesartan—Anaemia—Carmustine—melanoma	0.000407	0.00228	CcSEcCtD
Irbesartan—Dysphagia—Docetaxel—melanoma	0.000406	0.00228	CcSEcCtD
Irbesartan—Agitation—Carmustine—melanoma	0.000404	0.00227	CcSEcCtD
Irbesartan—Nausea—Vemurafenib—melanoma	0.000403	0.00226	CcSEcCtD
Irbesartan—Thrombocytopenia—Bleomycin—melanoma	0.000403	0.00226	CcSEcCtD
Irbesartan—Vision blurred—Temozolomide—melanoma	0.000401	0.00225	CcSEcCtD
Irbesartan—Myalgia—Dactinomycin—melanoma	0.0004	0.00225	CcSEcCtD
Irbesartan—Tremor—Temozolomide—melanoma	0.000398	0.00224	CcSEcCtD
Irbesartan—Discomfort—Dactinomycin—melanoma	0.000395	0.00222	CcSEcCtD
Irbesartan—Angina pectoris—Docetaxel—melanoma	0.000395	0.00222	CcSEcCtD
Irbesartan—Ill-defined disorder—Temozolomide—melanoma	0.000394	0.00221	CcSEcCtD
Irbesartan—Leukopenia—Carmustine—melanoma	0.000394	0.00221	CcSEcCtD
Irbesartan—Anaemia—Temozolomide—melanoma	0.000393	0.00221	CcSEcCtD
Irbesartan—Anorexia—Bleomycin—melanoma	0.000392	0.0022	CcSEcCtD
Irbesartan—Agitation—Temozolomide—melanoma	0.000391	0.00219	CcSEcCtD
Irbesartan—Angioedema—Temozolomide—melanoma	0.000388	0.00218	CcSEcCtD
Irbesartan—Hypotension—Bleomycin—melanoma	0.000384	0.00216	CcSEcCtD
Irbesartan—Oedema—Dactinomycin—melanoma	0.000384	0.00215	CcSEcCtD
Irbesartan—Malaise—Temozolomide—melanoma	0.000383	0.00215	CcSEcCtD
Irbesartan—Vertigo—Temozolomide—melanoma	0.000382	0.00214	CcSEcCtD
Irbesartan—Infection—Dactinomycin—melanoma	0.000381	0.00214	CcSEcCtD
Irbesartan—Leukopenia—Temozolomide—melanoma	0.00038	0.00214	CcSEcCtD
Irbesartan—Hypertension—Carmustine—melanoma	0.00038	0.00213	CcSEcCtD
Irbesartan—Neutropenia—Docetaxel—melanoma	0.000379	0.00213	CcSEcCtD
Irbesartan—Thrombocytopenia—Dactinomycin—melanoma	0.000376	0.00211	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Bleomycin—melanoma	0.000375	0.0021	CcSEcCtD
Irbesartan—Chest pain—Carmustine—melanoma	0.000374	0.0021	CcSEcCtD
Irbesartan—Myalgia—Carmustine—melanoma	0.000374	0.0021	CcSEcCtD
Irbesartan—Anxiety—Carmustine—melanoma	0.000373	0.0021	CcSEcCtD
Irbesartan—Cough—Temozolomide—melanoma	0.000371	0.00208	CcSEcCtD
Irbesartan—Paraesthesia—Bleomycin—melanoma	0.000369	0.00207	CcSEcCtD
Irbesartan—Weight increased—Docetaxel—melanoma	0.000369	0.00207	CcSEcCtD
Irbesartan—Hypertension—Temozolomide—melanoma	0.000367	0.00206	CcSEcCtD
Irbesartan—Dyspnoea—Bleomycin—melanoma	0.000367	0.00206	CcSEcCtD
Irbesartan—Anorexia—Dactinomycin—melanoma	0.000366	0.00205	CcSEcCtD
Irbesartan—Pneumonia—Docetaxel—melanoma	0.000364	0.00204	CcSEcCtD
Irbesartan—Arthralgia—Temozolomide—melanoma	0.000362	0.00203	CcSEcCtD
Irbesartan—Myalgia—Temozolomide—melanoma	0.000362	0.00203	CcSEcCtD
Irbesartan—Anxiety—Temozolomide—melanoma	0.000361	0.00202	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000359	0.00202	CcSEcCtD
Irbesartan—Oedema—Carmustine—melanoma	0.000359	0.00202	CcSEcCtD
Irbesartan—Discomfort—Temozolomide—melanoma	0.000358	0.00201	CcSEcCtD
Irbesartan—Decreased appetite—Bleomycin—melanoma	0.000357	0.00201	CcSEcCtD
Irbesartan—Infection—Carmustine—melanoma	0.000357	0.002	CcSEcCtD
Irbesartan—Acute coronary syndrome—Docetaxel—melanoma	0.000357	0.002	CcSEcCtD
Irbesartan—Renal failure—Docetaxel—melanoma	0.000356	0.002	CcSEcCtD
Irbesartan—Myocardial infarction—Docetaxel—melanoma	0.000355	0.00199	CcSEcCtD
Irbesartan—Dry mouth—Temozolomide—melanoma	0.000354	0.00199	CcSEcCtD
Irbesartan—Jaundice—Docetaxel—melanoma	0.000353	0.00198	CcSEcCtD
Irbesartan—Pain—Bleomycin—melanoma	0.000352	0.00197	CcSEcCtD
Irbesartan—Conjunctivitis—Docetaxel—melanoma	0.000352	0.00197	CcSEcCtD
Irbesartan—Thrombocytopenia—Carmustine—melanoma	0.000351	0.00197	CcSEcCtD
Irbesartan—Tachycardia—Carmustine—melanoma	0.00035	0.00197	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000349	0.00196	CcSEcCtD
Irbesartan—Oedema—Temozolomide—melanoma	0.000347	0.00195	CcSEcCtD
Irbesartan—Anaphylactic shock—Temozolomide—melanoma	0.000347	0.00195	CcSEcCtD
Irbesartan—Infection—Temozolomide—melanoma	0.000345	0.00194	CcSEcCtD
Irbesartan—Anorexia—Carmustine—melanoma	0.000342	0.00192	CcSEcCtD
Irbesartan—Hepatobiliary disease—Docetaxel—melanoma	0.000342	0.00192	CcSEcCtD
Irbesartan—Epistaxis—Docetaxel—melanoma	0.000341	0.00192	CcSEcCtD
Irbesartan—Nervous system disorder—Temozolomide—melanoma	0.00034	0.00191	CcSEcCtD
Irbesartan—Thrombocytopenia—Temozolomide—melanoma	0.00034	0.00191	CcSEcCtD
Irbesartan—Feeling abnormal—Bleomycin—melanoma	0.000339	0.0019	CcSEcCtD
Irbesartan—Agranulocytosis—Docetaxel—melanoma	0.000338	0.0019	CcSEcCtD
Irbesartan—CYP2D6—head—melanoma	0.000337	0.00736	CbGeAlD
Irbesartan—Skin disorder—Temozolomide—melanoma	0.000337	0.00189	CcSEcCtD
Irbesartan—Hypotension—Carmustine—melanoma	0.000335	0.00188	CcSEcCtD
Irbesartan—Hyperhidrosis—Temozolomide—melanoma	0.000335	0.00188	CcSEcCtD
Irbesartan—Decreased appetite—Dactinomycin—melanoma	0.000333	0.00187	CcSEcCtD
Irbesartan—Fatigue—Dactinomycin—melanoma	0.000331	0.00186	CcSEcCtD
Irbesartan—Anorexia—Temozolomide—melanoma	0.000331	0.00186	CcSEcCtD
Irbesartan—Pain—Dactinomycin—melanoma	0.000328	0.00184	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Carmustine—melanoma	0.000327	0.00184	CcSEcCtD
Irbesartan—Urticaria—Bleomycin—melanoma	0.000327	0.00183	CcSEcCtD
Irbesartan—Rhinitis—Docetaxel—melanoma	0.000326	0.00183	CcSEcCtD
Irbesartan—Body temperature increased—Bleomycin—melanoma	0.000325	0.00183	CcSEcCtD
Irbesartan—Hepatitis—Docetaxel—melanoma	0.000325	0.00182	CcSEcCtD
Irbesartan—Hypoaesthesia—Docetaxel—melanoma	0.000323	0.00181	CcSEcCtD
Irbesartan—Paraesthesia—Carmustine—melanoma	0.000322	0.00181	CcSEcCtD
Irbesartan—Pharyngitis—Docetaxel—melanoma	0.000322	0.00181	CcSEcCtD
Irbesartan—Urinary tract disorder—Docetaxel—melanoma	0.000321	0.0018	CcSEcCtD
Irbesartan—Dyspnoea—Carmustine—melanoma	0.00032	0.0018	CcSEcCtD
Irbesartan—Oedema peripheral—Docetaxel—melanoma	0.00032	0.0018	CcSEcCtD
Irbesartan—Somnolence—Carmustine—melanoma	0.000319	0.00179	CcSEcCtD
Irbesartan—Connective tissue disorder—Docetaxel—melanoma	0.000319	0.00179	CcSEcCtD
Irbesartan—Urethral disorder—Docetaxel—melanoma	0.000318	0.00179	CcSEcCtD
Irbesartan—Feeling abnormal—Dactinomycin—melanoma	0.000316	0.00177	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Temozolomide—melanoma	0.000316	0.00177	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dactinomycin—melanoma	0.000314	0.00176	CcSEcCtD
Irbesartan—Visual impairment—Docetaxel—melanoma	0.000313	0.00176	CcSEcCtD
Irbesartan—Decreased appetite—Carmustine—melanoma	0.000312	0.00175	CcSEcCtD
Irbesartan—Paraesthesia—Temozolomide—melanoma	0.000311	0.00175	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Carmustine—melanoma	0.00031	0.00174	CcSEcCtD
Irbesartan—Dyspnoea—Temozolomide—melanoma	0.000309	0.00174	CcSEcCtD
Irbesartan—Somnolence—Temozolomide—melanoma	0.000308	0.00173	CcSEcCtD
Irbesartan—Pain—Carmustine—melanoma	0.000307	0.00172	CcSEcCtD
Irbesartan—Constipation—Carmustine—melanoma	0.000307	0.00172	CcSEcCtD
Irbesartan—Dyspepsia—Temozolomide—melanoma	0.000305	0.00171	CcSEcCtD
Irbesartan—Abdominal pain—Dactinomycin—melanoma	0.000303	0.0017	CcSEcCtD
Irbesartan—Body temperature increased—Dactinomycin—melanoma	0.000303	0.0017	CcSEcCtD
Irbesartan—Hypersensitivity—Bleomycin—melanoma	0.000303	0.0017	CcSEcCtD
Irbesartan—Decreased appetite—Temozolomide—melanoma	0.000302	0.00169	CcSEcCtD
Irbesartan—Cardiac disorder—Docetaxel—melanoma	0.000301	0.00169	CcSEcCtD
Irbesartan—Flushing—Docetaxel—melanoma	0.000301	0.00169	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Temozolomide—melanoma	0.000299	0.00168	CcSEcCtD
Irbesartan—Fatigue—Temozolomide—melanoma	0.000299	0.00168	CcSEcCtD
Irbesartan—Pain—Temozolomide—melanoma	0.000297	0.00167	CcSEcCtD
Irbesartan—Constipation—Temozolomide—melanoma	0.000297	0.00167	CcSEcCtD
Irbesartan—Feeling abnormal—Carmustine—melanoma	0.000296	0.00166	CcSEcCtD
Irbesartan—Asthenia—Bleomycin—melanoma	0.000295	0.00166	CcSEcCtD
Irbesartan—Candesartan—ABCB1—melanoma	0.000295	0.27	CrCbGaD
Irbesartan—Angiopathy—Docetaxel—melanoma	0.000295	0.00165	CcSEcCtD
Irbesartan—Gastrointestinal pain—Carmustine—melanoma	0.000294	0.00165	CcSEcCtD
Irbesartan—Immune system disorder—Docetaxel—melanoma	0.000293	0.00165	CcSEcCtD
Irbesartan—Mediastinal disorder—Docetaxel—melanoma	0.000293	0.00164	CcSEcCtD
Irbesartan—Chills—Docetaxel—melanoma	0.000291	0.00164	CcSEcCtD
Irbesartan—Pruritus—Bleomycin—melanoma	0.000291	0.00163	CcSEcCtD
Irbesartan—Arrhythmia—Docetaxel—melanoma	0.00029	0.00163	CcSEcCtD
Irbesartan—PTGS1—lymph node—melanoma	0.000287	0.00627	CbGeAlD
Irbesartan—Feeling abnormal—Temozolomide—melanoma	0.000286	0.00161	CcSEcCtD
Irbesartan—Abdominal pain—Carmustine—melanoma	0.000284	0.00159	CcSEcCtD
Irbesartan—Body temperature increased—Carmustine—melanoma	0.000284	0.00159	CcSEcCtD
Irbesartan—Gastrointestinal pain—Temozolomide—melanoma	0.000284	0.00159	CcSEcCtD
Irbesartan—Erythema—Docetaxel—melanoma	0.000283	0.00159	CcSEcCtD
Irbesartan—Malnutrition—Docetaxel—melanoma	0.000283	0.00159	CcSEcCtD
Irbesartan—Hypersensitivity—Dactinomycin—melanoma	0.000283	0.00159	CcSEcCtD
Irbesartan—Dysgeusia—Docetaxel—melanoma	0.000277	0.00155	CcSEcCtD
Irbesartan—Urticaria—Temozolomide—melanoma	0.000276	0.00155	CcSEcCtD
Irbesartan—Asthenia—Dactinomycin—melanoma	0.000275	0.00155	CcSEcCtD
Irbesartan—Abdominal pain—Temozolomide—melanoma	0.000274	0.00154	CcSEcCtD
Irbesartan—Body temperature increased—Temozolomide—melanoma	0.000274	0.00154	CcSEcCtD
Irbesartan—Muscle spasms—Docetaxel—melanoma	0.000272	0.00153	CcSEcCtD
Irbesartan—Hypersensitivity—Carmustine—melanoma	0.000264	0.00149	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—melanoma	0.000262	0.00147	CcSEcCtD
Irbesartan—Vomiting—Bleomycin—melanoma	0.000261	0.00147	CcSEcCtD
Irbesartan—Anaemia—Docetaxel—melanoma	0.000261	0.00147	CcSEcCtD
Irbesartan—Rash—Bleomycin—melanoma	0.000259	0.00146	CcSEcCtD
Irbesartan—Dermatitis—Bleomycin—melanoma	0.000259	0.00145	CcSEcCtD
Irbesartan—Asthenia—Carmustine—melanoma	0.000258	0.00145	CcSEcCtD
Irbesartan—Hypersensitivity—Temozolomide—melanoma	0.000256	0.00144	CcSEcCtD
Irbesartan—Syncope—Docetaxel—melanoma	0.000253	0.00142	CcSEcCtD
Irbesartan—Leukopenia—Docetaxel—melanoma	0.000253	0.00142	CcSEcCtD
Irbesartan—Asthenia—Temozolomide—melanoma	0.000249	0.0014	CcSEcCtD
Irbesartan—Loss of consciousness—Docetaxel—melanoma	0.000248	0.0014	CcSEcCtD
Irbesartan—Cough—Docetaxel—melanoma	0.000247	0.00139	CcSEcCtD
Irbesartan—Diarrhoea—Carmustine—melanoma	0.000246	0.00138	CcSEcCtD
Irbesartan—Pruritus—Temozolomide—melanoma	0.000245	0.00138	CcSEcCtD
Irbesartan—Nausea—Bleomycin—melanoma	0.000244	0.00137	CcSEcCtD
Irbesartan—Hypertension—Docetaxel—melanoma	0.000244	0.00137	CcSEcCtD
Irbesartan—Vomiting—Dactinomycin—melanoma	0.000244	0.00137	CcSEcCtD
Irbesartan—Rash—Dactinomycin—melanoma	0.000242	0.00136	CcSEcCtD
Irbesartan—Chest pain—Docetaxel—melanoma	0.000241	0.00135	CcSEcCtD
Irbesartan—Myalgia—Docetaxel—melanoma	0.000241	0.00135	CcSEcCtD
Irbesartan—Arthralgia—Docetaxel—melanoma	0.000241	0.00135	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000239	0.00134	CcSEcCtD
Irbesartan—Dizziness—Carmustine—melanoma	0.000237	0.00133	CcSEcCtD
Irbesartan—Diarrhoea—Temozolomide—melanoma	0.000237	0.00133	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—melanoma	0.000235	0.00132	CcSEcCtD
Irbesartan—Anaphylactic shock—Docetaxel—melanoma	0.000231	0.0013	CcSEcCtD
Irbesartan—Oedema—Docetaxel—melanoma	0.000231	0.0013	CcSEcCtD
Irbesartan—Dizziness—Temozolomide—melanoma	0.000229	0.00129	CcSEcCtD
Irbesartan—Infection—Docetaxel—melanoma	0.000229	0.00129	CcSEcCtD
Irbesartan—Vomiting—Carmustine—melanoma	0.000228	0.00128	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—melanoma	0.000228	0.00128	CcSEcCtD
Irbesartan—Shock—Docetaxel—melanoma	0.000227	0.00127	CcSEcCtD
Irbesartan—Rash—Carmustine—melanoma	0.000226	0.00127	CcSEcCtD
Irbesartan—Nervous system disorder—Docetaxel—melanoma	0.000226	0.00127	CcSEcCtD
Irbesartan—Dermatitis—Carmustine—melanoma	0.000226	0.00127	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—melanoma	0.000226	0.00127	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—melanoma	0.000225	0.00126	CcSEcCtD
Irbesartan—Headache—Carmustine—melanoma	0.000225	0.00126	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—melanoma	0.000224	0.00126	CcSEcCtD
Irbesartan—Vomiting—Temozolomide—melanoma	0.000221	0.00124	CcSEcCtD
Irbesartan—Anorexia—Docetaxel—melanoma	0.00022	0.00123	CcSEcCtD
Irbesartan—Rash—Temozolomide—melanoma	0.000219	0.00123	CcSEcCtD
Irbesartan—Dermatitis—Temozolomide—melanoma	0.000219	0.00123	CcSEcCtD
Irbesartan—Headache—Temozolomide—melanoma	0.000217	0.00122	CcSEcCtD
Irbesartan—Hypotension—Docetaxel—melanoma	0.000216	0.00121	CcSEcCtD
Irbesartan—Nausea—Carmustine—melanoma	0.000213	0.0012	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—melanoma	0.00021	0.00118	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—melanoma	0.000207	0.00116	CcSEcCtD
Irbesartan—Nausea—Temozolomide—melanoma	0.000206	0.00116	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—melanoma	0.000206	0.00115	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—melanoma	0.000205	0.00115	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—melanoma	0.000203	0.00114	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—melanoma	0.000201	0.00113	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—melanoma	0.000199	0.00112	CcSEcCtD
Irbesartan—Losartan—ALB—melanoma	0.000199	0.182	CrCbGaD
Irbesartan—Fatigue—Docetaxel—melanoma	0.000199	0.00112	CcSEcCtD
Irbesartan—Pain—Docetaxel—melanoma	0.000197	0.00111	CcSEcCtD
Irbesartan—Constipation—Docetaxel—melanoma	0.000197	0.00111	CcSEcCtD
Irbesartan—Feeling abnormal—Docetaxel—melanoma	0.00019	0.00107	CcSEcCtD
Irbesartan—Losartan—ABCB1—melanoma	0.00019	0.174	CrCbGaD
Irbesartan—Gastrointestinal pain—Docetaxel—melanoma	0.000189	0.00106	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—melanoma	0.000182	0.00102	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—melanoma	0.000182	0.00102	CcSEcCtD
Irbesartan—Hypersensitivity—Docetaxel—melanoma	0.00017	0.000954	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—melanoma	0.000166	0.000929	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—melanoma	0.000163	0.000916	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—melanoma	0.000158	0.000886	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—melanoma	0.000153	0.000857	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—melanoma	0.000147	0.000824	CcSEcCtD
Irbesartan—Rash—Docetaxel—melanoma	0.000145	0.000817	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—melanoma	0.000145	0.000816	CcSEcCtD
Irbesartan—Headache—Docetaxel—melanoma	0.000145	0.000812	CcSEcCtD
Irbesartan—Nausea—Docetaxel—melanoma	0.000137	0.000769	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—NFKB1—melanoma	1.1e-05	3.38e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTAP—melanoma	1.1e-05	3.37e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1B—melanoma	1.09e-05	3.35e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—melanoma	1.08e-05	3.32e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—melanoma	1.08e-05	3.3e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—melanoma	1.07e-05	3.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—melanoma	1.06e-05	3.27e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP17A1—melanoma	1.06e-05	3.25e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PRKCA—melanoma	1.04e-05	3.21e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.04e-05	3.2e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—melanoma	1.04e-05	3.18e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ERCC2—melanoma	1.03e-05	3.18e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MDM2—melanoma	1.03e-05	3.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	1.03e-05	3.16e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—melanoma	1.03e-05	3.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—VCAN—melanoma	1.03e-05	3.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FN1—melanoma	1.02e-05	3.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—VCAN—melanoma	1.02e-05	3.13e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—melanoma	1.02e-05	3.13e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1A—melanoma	1e-05	3.09e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CB—melanoma	1e-05	3.09e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—melanoma	1e-05	3.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH1—melanoma	1e-05	3.08e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—melanoma	9.98e-06	3.07e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNA11—melanoma	9.98e-06	3.07e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NFKB1—melanoma	9.98e-06	3.07e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—melanoma	9.92e-06	3.05e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—melanoma	9.89e-06	3.04e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—melanoma	9.86e-06	3.03e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CD80—melanoma	9.81e-06	3.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—melanoma	9.79e-06	3.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—melanoma	9.79e-06	3.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—melanoma	9.79e-06	3.01e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PHGDH—melanoma	9.77e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LUM—melanoma	9.77e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FASN—melanoma	9.76e-06	3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLA2G6—melanoma	9.69e-06	2.98e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGF—melanoma	9.67e-06	2.97e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—melanoma	9.65e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	9.65e-06	2.97e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—melanoma	9.61e-06	2.95e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—melanoma	9.6e-06	2.95e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—melanoma	9.58e-06	2.95e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HPSE—melanoma	9.58e-06	2.95e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—melanoma	9.45e-06	2.9e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—melanoma	9.42e-06	2.9e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CUBN—melanoma	9.41e-06	2.89e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—melanoma	9.32e-06	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	9.31e-06	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNAQ—melanoma	9.27e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD44—melanoma	9.27e-06	2.85e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—melanoma	9.23e-06	2.84e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—melanoma	9.22e-06	2.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—melanoma	9.2e-06	2.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—melanoma	9.19e-06	2.82e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—melanoma	9.17e-06	2.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDHD—melanoma	9.08e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CSPG4—melanoma	9.08e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BSG—melanoma	9.08e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.08e-06	2.79e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	9e-06	2.77e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK1—melanoma	8.99e-06	2.76e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—melanoma	8.99e-06	2.76e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—melanoma	8.99e-06	2.76e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—melanoma	8.96e-06	2.76e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—melanoma	8.96e-06	2.75e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—melanoma	8.94e-06	2.75e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—melanoma	8.9e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1B1—melanoma	8.89e-06	2.73e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPAM—melanoma	8.8e-06	2.7e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—melanoma	8.73e-06	2.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—VCAN—melanoma	8.71e-06	2.68e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—melanoma	8.69e-06	2.67e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—melanoma	8.67e-06	2.67e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP17A1—melanoma	8.67e-06	2.67e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAP2K1—melanoma	8.66e-06	2.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKB1—melanoma	8.63e-06	2.65e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CD—melanoma	8.6e-06	2.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP17A1—melanoma	8.6e-06	2.64e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.57e-06	2.63e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—melanoma	8.56e-06	2.63e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—melanoma	8.49e-06	2.61e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	8.48e-06	2.61e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—melanoma	8.46e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	8.37e-06	2.57e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.24e-06	2.53e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGF2—melanoma	8.24e-06	2.53e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNA11—melanoma	8.19e-06	2.52e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—melanoma	8.17e-06	2.51e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK1—melanoma	8.15e-06	2.51e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—melanoma	8.15e-06	2.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNA11—melanoma	8.12e-06	2.5e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FASN—melanoma	8.01e-06	2.46e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	7.96e-06	2.45e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FASN—melanoma	7.95e-06	2.44e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—melanoma	7.89e-06	2.42e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—melanoma	7.88e-06	2.42e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.85e-06	2.41e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—melanoma	7.83e-06	2.41e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—melanoma	7.82e-06	2.4e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—melanoma	7.8e-06	2.4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—melanoma	7.76e-06	2.38e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—melanoma	7.74e-06	2.38e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—melanoma	7.71e-06	2.37e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—melanoma	7.7e-06	2.37e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNAQ—melanoma	7.61e-06	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD44—melanoma	7.61e-06	2.34e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—melanoma	7.6e-06	2.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNAQ—melanoma	7.55e-06	2.32e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD44—melanoma	7.55e-06	2.32e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—melanoma	7.54e-06	2.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CB—melanoma	7.5e-06	2.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLA2G6—melanoma	7.48e-06	2.3e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—melanoma	7.41e-06	2.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	7.39e-06	2.27e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP17A1—melanoma	7.35e-06	2.26e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	7.32e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—melanoma	7.32e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1B1—melanoma	7.3e-06	2.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.25e-06	2.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1B1—melanoma	7.24e-06	2.22e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—melanoma	7.21e-06	2.22e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—melanoma	7.21e-06	2.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—melanoma	7.21e-06	2.22e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CD—melanoma	7.18e-06	2.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	7.15e-06	2.2e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—melanoma	7.09e-06	2.18e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—melanoma	7.07e-06	2.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK1—melanoma	7.05e-06	2.17e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—melanoma	7.05e-06	2.17e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—melanoma	7.04e-06	2.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNA11—melanoma	6.94e-06	2.13e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—melanoma	6.91e-06	2.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—melanoma	6.9e-06	2.12e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—melanoma	6.89e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FASN—melanoma	6.79e-06	2.09e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—melanoma	6.78e-06	2.08e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PRKCA—melanoma	6.74e-06	2.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—VCAN—melanoma	6.72e-06	2.07e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—melanoma	6.71e-06	2.06e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ERCC2—melanoma	6.68e-06	2.05e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—melanoma	6.68e-06	2.05e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—melanoma	6.66e-06	2.05e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—melanoma	6.65e-06	2.04e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—melanoma	6.54e-06	2.01e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—melanoma	6.52e-06	2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—melanoma	6.5e-06	2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—melanoma	6.48e-06	1.99e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNAQ—melanoma	6.45e-06	1.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD44—melanoma	6.45e-06	1.98e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKB1—melanoma	6.45e-06	1.98e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.39e-06	1.96e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—melanoma	6.37e-06	1.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.32e-06	1.94e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—melanoma	6.26e-06	1.92e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CB—melanoma	6.26e-06	1.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.26e-06	1.92e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—melanoma	6.2e-06	1.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1B1—melanoma	6.18e-06	1.9e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—melanoma	6.12e-06	1.88e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—melanoma	6.01e-06	1.85e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—melanoma	5.96e-06	1.83e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—melanoma	5.92e-06	1.82e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—melanoma	5.85e-06	1.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—melanoma	5.8e-06	1.78e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—melanoma	5.78e-06	1.78e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—melanoma	5.78e-06	1.78e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP17A1—melanoma	5.67e-06	1.74e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—melanoma	5.66e-06	1.74e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—melanoma	5.54e-06	1.7e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.54e-06	1.7e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—melanoma	5.54e-06	1.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PRKCA—melanoma	5.53e-06	1.7e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ERCC2—melanoma	5.49e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PRKCA—melanoma	5.48e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.46e-06	1.68e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ERCC2—melanoma	5.44e-06	1.67e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—melanoma	5.42e-06	1.67e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—melanoma	5.41e-06	1.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—melanoma	5.39e-06	1.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNA11—melanoma	5.35e-06	1.65e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—melanoma	5.28e-06	1.62e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK1—melanoma	5.27e-06	1.62e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—melanoma	5.27e-06	1.62e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FASN—melanoma	5.24e-06	1.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—melanoma	5.15e-06	1.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—melanoma	5.09e-06	1.57e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—melanoma	5.09e-06	1.57e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—melanoma	5e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNAQ—melanoma	4.98e-06	1.53e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD44—melanoma	4.98e-06	1.53e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—melanoma	4.98e-06	1.53e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1B1—melanoma	4.77e-06	1.47e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PRKCA—melanoma	4.69e-06	1.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ERCC2—melanoma	4.65e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CD—melanoma	4.64e-06	1.43e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—melanoma	4.58e-06	1.41e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—melanoma	4.57e-06	1.41e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.51e-06	1.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—melanoma	4.42e-06	1.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—melanoma	4.33e-06	1.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—melanoma	4.3e-06	1.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—melanoma	4.23e-06	1.3e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—melanoma	4.18e-06	1.29e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—melanoma	4.15e-06	1.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—melanoma	4.05e-06	1.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CB—melanoma	4.04e-06	1.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—melanoma	4.01e-06	1.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—melanoma	3.93e-06	1.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.85e-06	1.18e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—melanoma	3.82e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CD—melanoma	3.81e-06	1.17e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CD—melanoma	3.78e-06	1.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—melanoma	3.76e-06	1.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—melanoma	3.73e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—melanoma	3.73e-06	1.15e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—melanoma	3.67e-06	1.13e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PRKCA—melanoma	3.62e-06	1.11e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ERCC2—melanoma	3.59e-06	1.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—melanoma	3.54e-06	1.09e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—melanoma	3.49e-06	1.07e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CB—melanoma	3.32e-06	1.02e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CB—melanoma	3.29e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—melanoma	3.29e-06	1.01e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—melanoma	3.26e-06	1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CD—melanoma	3.23e-06	9.92e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—melanoma	3.19e-06	9.79e-06	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—melanoma	3.12e-06	9.59e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—melanoma	2.87e-06	8.82e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—melanoma	2.84e-06	8.74e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—melanoma	2.83e-06	8.71e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CB—melanoma	2.81e-06	8.65e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—melanoma	2.79e-06	8.57e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—melanoma	2.73e-06	8.41e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CD—melanoma	2.49e-06	7.66e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—melanoma	2.47e-06	7.58e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—melanoma	2.46e-06	7.56e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—melanoma	2.43e-06	7.47e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CB—melanoma	2.17e-06	6.67e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—melanoma	2.15e-06	6.61e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—melanoma	2.02e-06	6.22e-06	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—melanoma	2.01e-06	6.19e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—melanoma	2.01e-06	6.17e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—melanoma	1.88e-06	5.77e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—melanoma	1.71e-06	5.27e-06	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—melanoma	1.65e-06	5.08e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—melanoma	1.64e-06	5.04e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—melanoma	1.4e-06	4.31e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—melanoma	1.32e-06	4.07e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—melanoma	1.08e-06	3.32e-06	CbGpPWpGaD
